Movers and SHAKERS
Onconova Therapeutics (ONTX)
Once Fall, Twice Stand Up
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focused on discovering and developing small molecule inhibitors to treat cancer. The lead product candidate rigosertib is in Phase 3 clinical trial for patients with higher risk myelodysplastic syndromes (MDS).
Ahu Demir, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Onconova’s main focus is MDS. Onconova Therapeutics is currently focused on completing a Phase 3 study (INSPIRE) with rigosertib, a RAS pathway inhibitor, for the treatment of 2nd line high-risk myelodysplastic syndrome (HR-MDS). MDS is a blood disorder caused by malfunctioning of the bone marrow, which fails to make enough normal blood cells. In March 2019, the company achieved 75 percent completion of patient enrollment. Full enrolment is expected in H2 2019, data readout to follow in 2020.
- Clinical Benefit in Selected Patient Population. Onconova’s Phase 3 clinical trial (ONTIME) showed lackluster survival benefit in HR-MDS patients based on data readout in 2014. However, post-hoc analysis of the data suggested...
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.